In this case, the tests determine whether a patient’s tumor has a genetic change that is targeted by a specific drug. REDWOOD CITY, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved Guardant360 ® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid biopsy approval … The Guardant360 CDx is also approved as a … Guardant360 CDx, made by Guardant Health, was approved as a companion diagnostic for osimertinib (Tagrisso), a lung cancer therapy. Guardant Health CEO Helmy Eltoukhy said: “The FDA approval of Guardant360 CDx is a landmark decision, demonstrating the value liquid biopsy delivers to … If approved, the Guardant360 assay could be the first FDA-approved comprehensive liquid biopsy. Guardant Health has hit an important milestone with its liquid biopsy test. In the race to be first to get US approval for a pan-cancer liquid biopsy the field had narrowed to just two serious contenders: Roche and Guardant Health. The FDA has approved Guardant360 CDx for comprehensive genomic profiling in patients with any solid malignant neoplasm, according to Guardant Health, the developer of the liquid biopsy. Guardant360 CDx is a single-site assay performed at Guardant Health, Inc. Approval Order: Approval Order: Summary: Summary of Safety and Effectiveness: Labeling: Labeling Labeling Part 2: Supplements: - - For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. The Redwood City, CA-based company won a nod from FDA for the Guardant360 CDX, making it the first liquid biopsy test for comprehensive tumor mutation profiling across all solid cancers to obtain approval. The FDA has approved Guardant Health’s Guardant360® CDx liquid biopsy as the first blood-based comprehensive tumor mutation profiling test in … Guardant scores FDA approval for liquid biopsy test In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to … SINGAPORE, Aug. 7, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360 ® CDx, for tumor mutation profiling in patients across all solid cancers.. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is … On Friday the latter company won, and the FDA’s rubber-stamp should boost usage of the Guardant360 blood test. The Guardant360® assay, the leading comprehensive liquid biopsy, received an Expedited Access Pathway (EAP) designation from the United States Food and Drug Administration, Guardant Health announced.